Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy

NINOSKA N. SILVA, MPAS, PA-C, AND CATHY ENG, MD, FACP

From The University of Texas MD Anderson Cancer Center, Houston, Texas

Authors' disclosures of potential conflict of interest are found at the end of this article.

Correspondence to: Ninoska N. Silva, MPAS, PA-C, MD Anderson Cancer Center, Department of GI Medical Oncology, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030. E-mail: NNSilva@mdanderson.org

© 2012 Harborside Press®

Cancer of the anal canal is an uncommon malignancy comprising 2% of all gastrointestinal malignancies; most of these cancers are of the squamous cell histologic subtype (Jemal et al., 2008; Bilimoria et al., 2009; Horner et al., 2009). In most cases, patients present with localized disease that is often curable with concurrent chemoradiation therapy, reserving abdominal perineal resection for salvage therapy. Unfortunately, a minority of patients (12%) will have metastatic disease at initial presentation (Ryan & Willet, 2001; Horner et al., 2009). Due to the lack of evidence-based data and an unknown optimal duration of therapy, treatment decisions are often founded on more common squamous cell carcinomas (SCCs) such as cervical and lung cancer.

Limited Data to Guide Treatment

In this article, we present the case of a patient with metastatic squamous cell carcinoma of the anal canal that progressed shortly following chemoradiation therapy with curative intent.

A key point in this patient's treatment history was the 3-week treatment delay during her concurrent chemoradiation therapy. It is well known that treatment delays should be minimized as much as possible during radiation therapy of the anal canal, and that significant delays negatively impact patient outcome (Graf et al., 2003). In addition, recent data from the phase III ACT II trial have shown no additional benefit in disease-free or overall survival for adjuvant fluorouracil (5-FU)-based chemotherapy following definitive chemoradiation therapy for curative intent (James et al., 2009).

Because metastasis from squamous cell carcinoma of the anal canal is infrequent, there are limited data to guide treatment recommendations (Table 1). The most frequently reported systemic chemotherapy regimen is 5-FU/cisplatin, which has successfully shown a partial response rate as high as 50% and a complete response rate of 15% when used to treat locally recurrent or metastatic disease (Deniaud-Alexandre et al., 2003; Ajani et al., 2008; Eng & Pathak, 2008; Jemal et al., 2008; James et al., 2009; Lynch et al., 2010). In our patient's case, 5-FU/cisplatin was pro-

Table 1. Treatment for Metastatic Squamous Cell Carcinoma of the Anal Canal^a

Agent	Study type (Reference)	Regimen	No. of patients	RR	TTP	MS
5-FU + cisplatin	Case series (Faivre, 1999)	<u>5-FU</u> : 1 g/m ² /d x 5 days <u>Cis</u> : 100 mg/m ² day 2 (q4wk)	19	66%	NA	34.5 mo
Single-agent paclitaxel	Case series (Alcindor, 2008)	175 mg/m ² (q3wk)	5	60%	NA	NA
Carboplatin + paclitaxel + 5-FU (SCC of any primary site)	Phase II (Hainsworth, 2001)	<u>Carb</u> : AUC 6 IV days 1,22 <u>Pac</u> : 200 mg/m ² over 1 hr <u>5-FU</u> : 225 mg/m ² day, 24-hr CI days 1-35 (q6wk)	7	90%	NA	34.5 mo
Single-agent carboplatin	Case report (Evans, 1993)	NA	1	NA	9 mo	NA
Irinotecan + cetuximab	Case report (Phan & Hoff, 2007)	<u>Irin</u> : 180 mg/m ² q2wk <u>Cet</u> : 400 mg/m ² wk 1, then 250 mg/m ² weekly	1	NA	8 mo	NA

Note. RR = response rate; TTP = time to progression; MS = median survival; 5-FU = fluorouracil; Cis = cisplatin; NA = not available; SCC = squamous cell carcinoma; Carb = carboplatin; AUC = area under the concentration-time curve; Pac = paclitaxel; CI = continuous infusion; Irino = irinotecan; Cet = cetuximab.

^aThere are no trials completed specifically for second-line and higher treatment of metastatic squamous cell carcinoma of the anal canal. ^bOut of 60 patients total (with squamous cell carcinoma of different primaries), 7 had anal squamous cell carcinoma.

vided as an alternative due to her platinum-naïve status. A well-known radiation sensitizer, 5-FU/cisplatin was provided for palliation of pain due to the primary tumor with the interim development of distant metastatic disease.

Trials in Cancers of Similar Histologic Subtype

Other chemotherapy regimens considered for our patient were largely based on data extrapolated from other cancers of similar histologic subtype, i.e., non-small cell lung cancer (NSCLC) and head and neck cancer (Table 2). Unfortunately, the combination of carboplatin/paclitaxel resulted in our patient's continued distant disease progression. Therefore, we chose to pursue the therapeutic recommendation of the vinorelbine, cisplatin, and cetuximab (VCC) regimen based on data from a randomized phase II study of cisplatin and vinorelbine with or without weekly cetuximab as first-line therapy for NSCLC (Rosell et al., 2008). The vinorelbine/cisplatin combination is an accepted regimen for NSCLC, and in this phase II study the addition of cetuximab increased the response rate (35% vs. 28%), the median progression-free survival

(5.0 vs. 4.6 months, HR = 0.71), and the median overall survival (8.3 vs. 7.3 months, hazard ratio = 0.71) (Rosell et al., 2008; Van Damme et al., 2008). The pivotal phase III FLEX trial (vinorelbine/cisplatin with or without cetuximab) validated the phase II findings in patients with treatment-naïve stage IIIB/IV NSCLC. Those who received the cetuximab combination were found to have superior overall survival (11.3 vs. 10.1 months, $p = .044$) and response (36% vs. 29%, $p = .010$) (Pirker et al., 2009).

A second phase III trial (BMS099) evaluated the role of epidermal growth factor receptor (EGFR) inhibition in treatment-naïve patients to carboplatin (AUC = 6) and either paclitaxel (225 mg/m²) or docetaxel (75 mg/m²) with a randomization to weekly cetuximab (Lynch et al., 2010). The investigators failed to fulfill the primary endpoint of progression-free survival ($p = .236$) but were able to determine improved response rate (26% vs. 17%, $p = .007$) for the investigational arm. Based on the premise of these studies, EGFR inhibition in combination with chemotherapy seems promising. Additional studies should be pursued to determine predictive markers of response. Unlike in colorectal cancer, the presence

Case Study

Ms. S.G., a 56-year-old woman with a poorly differentiated squamous cell carcinoma of the anal canal, American Joint Committee on Cancer stage III (T2, N1, M0), was initially diagnosed in December, 2007 at an outside institution after she had noted blood in her stool for approximately 6 months. Her medical history was unremarkable. She had no known history of HIV or other sexually transmitted diseases. At the time of presentation, Ms. S.G. had an Eastern Cooperative Oncology Group performance status of 1 related to cancer-related pain. Her appetite and weight were both stable.

A complete colonoscopy demonstrated a large, immobile, ulcerated, firm, 4-cm lesion in the distal rectum, arising from the anal canal. Initial staging positron emission tomography/computed tomography (PET/CT) scan revealed a hypermetabolic inferior anorectal mass with left perirectal and presacral nodal metastases. There was no definite evidence of distant metastatic disease.

Ms. S.G. received chemoradiation treatment following her diagnostic studies, with a total dose of 45 Gy over 26 fractions to the pelvis with concurrent infusional fluorouracil (5-FU; 2,450 mg over 7 days) and mitomycin C (12 mg/m² on day 1) at an outside institution. However, during her chemoradiation therapy, Ms. S.G. experienced a 3-week treatment break due to severe radiation dermatitis, as recommended by her outside treating oncologist.

Upon treatment completion, Ms. S.G. un-

Figure 1. Contrast-enhanced axial MRI image of the lower pelvis. (A) Pretreatment, complex mass at the rectosigmoid junction measuring approximately 7.6 × 4.9 × 7.3 cm³. (B) Posttreatment, large necrotic mass measuring 3–4 cm in greatest dimension.

of the *KRAS* mutation does not appear to exist in SCC of the anal canal (Van Damme et al., 2008). However, extensive molecular marker analysis is limited at this time (Alvarez et al., 2006; Ajani et al., 2008).

Conclusion

We believe this to be the first case study reported using the VCC combination in metastatic SCC of the anal canal. We recognize that a small series of case studies have been reported using cetuximab as a single agent or in combination with irinotecan as approved for use in metastatic

colorectal adenocarcinoma with mild therapeutic benefit (Ajani et al., 2010). In this heavily pretreated patient, the short course of the VCC chemotherapy regimen resulted in a significant response to therapy and was well tolerated. Our treatment indicates the potential benefits of vinorelbine/cisplatin when combined with EGFR inhibition in the setting of locally recurrent or metastatic squamous cell carcinoma of the anal canal. EGFR inhibition has great promise in the treatment of metastatic squamous cell carcinoma of the anal canal, and in our patient's case, was tolerated well.

derwent a biopsy of the anal canal, which revealed no evidence of residual malignancy. As recommended by her treating oncologist, she received four additional cycles of adjuvant infusional 5-FU in combination with leucovorin. Shortly thereafter, Ms. S.G. developed progressive pelvic pain. She underwent a second PET/CT scan, revealing mixed findings: interval resolution of abnormal standardized uptake value (SUV) activity at the primary tumor in the anal canal, but an increase in the size and SUV of nodal disease within the left perirectal and presacral regions. A CT-guided biopsy noted a perirectal abscess requiring drainage but was inconclusive for disease recurrence; Ms. S.G. was treated with IV antibiotics.

Six weeks later, repeat radiographic imaging noted additional changes suspicious for regional recurrence, which was biopsy-confirmed. Ms. S.G. was subsequently referred to MD Anderson Cancer Center for consideration of salvage pelvic exenteration.

On physical exam a mass was palpated in the left lower quadrant, but there was no evidence of inguinal adenopathy. On digital rectal exam there was notable external erythema with a fixed mass and moderate sphincter tone. A chest CT scan showed no definite evidence of metastatic disease, but an MRI of the abdomen/pelvis indicated the presence of a complex partially necrotic mass ($7.6 \times 4.9 \times 7.3 \text{ cm}^3$) extending to the rectosigmoid junction, inseparable from the left lateral bowel wall, with partial encasement of the bowel. In addition, there was infiltration of the left piriformis muscle and cervix consistent with local recurrence. She was referred to medical oncology and radiation oncology for consideration of reirradiation with concurrent neoadjuvant chemotherapy for palliation and possible surgical resection.

In early December 2008, Ms. S.G. received intensity-modulated radiation therapy (IMRT), with a total dose of 27 Gy over 18 fractions. She received concurrent infusional 5-FU at $300 \text{ mg/m}^2/\text{day}$, from Monday to Friday, on the days of radiation. She also received a weekly bolus dose of cisplatin at

Figure 2. Contrast-enhanced axial CT images of the lung. (A) Subcentimeter nodular opacity in the left upper lobe. (B) Subcentimeter opacity in the right upper lung lobe.

20 mg/m^2 . The intent was to treat to 30 Gy, but the patient deferred further treatment early due to anorectal irritation. She then underwent restaging with a PET/CT scan and a pelvic MRI in February 2009, revealing radiographic partial response of the known pelvic recurrence and reduced pelvic pain (Figures 1A and 1B). Unfortunately, in the interim, she developed multiple bilateral liver lesions and punctate pulmonary nodules consistent with distant disease (Figures 2A, 2B, and 3A).

Ms. S.G. proceeded to undergo systemic chemotherapy with carboplatin at an area under the concentration-time curve of 5 and

paclitaxel at 175 mg/m² day 1, every 21 days. She tolerated the treatment well. After three cycles of chemotherapy, radiographic imaging indicated a mixed response to treatment: interval resolution of the pulmonary nodules, stability of disease in the pelvic mass, but progression of the hepatic metastases.

Given Ms. S.G.'s continuing excellent performance status, further treatment was recommended. Based on recent published literature, a regimen of cisplatin at 80 mg/m² day 1, vinorelbine at 25 mg/m² day 1 (repeated every 28 days), and weekly cetuximab (VCC) at 250 mg/m² was initiated. Remarkably, following three cycles of treatment, despite receiving multiple prior lines of chemotherapy,

her restaging CT scan demonstrated complete radiographic response of the intrathoracic disease, stable response of the anorectal mass, and near-complete resolution of the hepatic lesions (Figures 3A and 3B).

Overall, Ms. S.G. had tolerated her treatment very well. Given her response and tolerability, she was evaluated again for curative surgical resection. However, she opted to receive the VCC regimen closer to home and was lost to follow-up. Unfortunately, we were unable to obtain medical records confirming if she indeed received additional treatment as recommended. Ms. S.G. was noted to have passed away due to progression of her disease approximately 6 months later.

Figure 3. Contrast-enhanced axial CT image of the liver. (A) Pretreatment, multiple bilateral liver lesions. (B) Posttreatment, near-complete resolution of liver lesions.

Table 2. Systemic Regimens Shown to Have Activity in the Treatment of Metastatic Squamous Cell Carcinomas in Other Primary Tumor Sites

Site and agent	Study type (Reference)	Regimen	No. of patients	RR	TTP	MS
<i>Head and neck</i>						
Docetaxel	Phase II (Couteau, 1999)	100 mg/m ² over 1 hr q3wk	24	20.8%	11.7 wk	6.7 mo
Single-agent methotrexate	Phase III (Schornagel, 1995)	40 mg/m ² weekly	133	16%	3 mo	6 mo
Cetuximab + cisplatin or carboplatin with 5-FU	Pooled analysis (Vermorken, 2008)	<u>Cet</u> : 400 mg/m ² then 250 mg/m ² weekly <u>Cis</u> : 100 mg/m ² over 1 hr <u>Carb</u> : AUC 5 over 1 hr <u>5-FU</u> : 1,000 mg/m ² /day x 4 days (q3wk)	222	36%	5.6 mo	10.1 mo
Paclitaxel + carboplatin	Phase II (Fountzilas, 1997)	<u>Pac</u> : 175 mg/m ² over 3 hr <u>Carb</u> : AUC 6 over 30–60 min	49	57% (NPC) 23% (non-NPC)	16.5 mo 4.3 mo	NA 7.3
Paclitaxel, ifosfamide, carboplatin	Phase II (Shin, 2002)	<u>Pac</u> : 175 mg/m ² over 3 hr <u>Ifos</u> : 1,000 mg/m ² over 2 hr, days 1–3 w/mesna 200 mg/m ² before, 400 mg/m ² after <u>Carb</u> : AUC 6 over 30 min	52	59%–81%	3.7 mo	9.1 mo
<i>NSCLC</i>						
Carboplatin + paclitaxel + bevacizumab	Phase III (Sandler, 2006)	<u>Carb</u> : AUC 6 <u>Pac</u> : 200 mg/m ² <u>Bev</u> : 15 mg/kg (q3wk)	842	35%	6.2 mo	12.3 mo
Paclitaxel + carboplatin	Phase II (Kelly, 2001)	<u>Pac</u> : 225 mg/m ² over 3 hr <u>Carb</u> : AUC 6 over 30–60 min (q3wk)	206	25%	4 mo	8.6 mo
Gemcitabine + cisplatin + bevacizumab	Phase III (Reck, 2010)	<u>Gem</u> : 1,000 mg/m ² over 30 min days 1,8 <u>Cis</u> : 60–100 mg/m ² over 2 hr day 1 <u>Bev</u> : 7.5 mg/kg day 1 (q3wk)	345 (1,043)	34%	6.7 mo	NA
Pemetrexed + bevacizumab	Phase II (Herbst, 2007)	<u>Pem</u> : 500 mg/m ² over 10 min day 1 <u>Bev</u> : 7.5–15 mg/kg IV day 1 <u>Oral folate</u> : 350 µg daily <u>Vitamin B₁₂</u> : 1,000 µg IM q9wk <u>Dex</u> : 4 mg bid days 1,2	128	15%–41%	4.75 mo	8 mo
Docetaxel + carboplatin	Phase III (Fossella, 2003)	<u>Doc</u> : 75 mg/m ² IV over 1 hr followed by <u>Carb</u> : AUC 6 over 30–60 min (q3wk)	406	23.9%	5 mo	9.4 mo

Table 2. Systemic Regimens Shown to Have Activity in the Treatment of Metastatic Squamous Cell Carcinomas in Other Primary Tumor Sites (cont.)

Site and agent	Study type (Reference)	Regimen	No. of patients	RR	TTP	MS
<i>NSCLC</i>						
Docetaxel + cisplatin	Phase III (Fossella, 2003)	<u>Doc</u> : 75 mg/m ² over 1 hr <u>Cis</u> : 75 mg/m ² over 2 hr (q3wk)	408	31.6%	5.5 mo	11.3 mo
Cisplatin + gemcitabine	Phase III (Sandler, 2000)	<u>Cis</u> : 60-100 mg/m ² over 2 hr day 1 <u>Gem</u> : 1,000 mg/m ² over 30 min days 1,8 (q3wk)	260	30.4%	5.6 mo	9.1 mo
Carboplatin + gemcitabine	Phase II (Zatloukal, 2003)	<u>Carb</u> : AUC 5 IV over 30-60 min day 1 <u>Gem</u> : 1,000-1,200 mg/m ² over 30 min days 1,8 (q3wk)	88	29.2%	4.75 mo	8 mo
Pemetrexed + gemcitabine	Phase II (Monnerat, 2004)	<u>Pem</u> : 500 mg/m ² days 1,8 <u>Gem</u> : 1,000-1,250 mg/m ² days 1,8 <u>Oral folate</u> : 350 µg daily <u>Vitamin B₁₂</u> : 1,000 µg IM (q3wk)	52	15%-41%	4.75 mo	8 mo
Gemcitabine + vinorelbine	Phase III (Gridelli, 2003)	<u>Gem</u> : 1,000 mg/m ² IV over 30 min <u>Vin</u> : 25 mg/m ² over 10 min days 1,8 (q3wk)	232	21%	4.25 mo	7.5 mo
Pemetrexed + carboplatin, or oxaliplatin	Phase II (Zinner, 2010)	<u>Pem</u> : 500 mg/m ² over 10 min followed by <u>Carb</u> : AUC 6 IV over 30-60 min <u>Oxali</u> : 120 mg/m ²	129	17.2%	4.7 mo	9.8 mo
Vinorelbine + cisplatin	Phase III (Kelly, 2001)	<u>Vin</u> : 25 mg/m ² /wk IV over 10 min <u>Cis</u> : 100 mg/m ² IV (q4wk)	202	28%	4 mo	8.1 mo
Cetuximab + vinorelbine + cisplatin	Phase II (Rosell, 2008)	<u>Cet</u> : 500 mg/m ² IV wk 1, then 250 mg/m ² weekly <u>Vin</u> : 25 mg/m ² IV days 1,8 <u>Cis</u> : 80 mg/m ² IV day 1 (q3wk)	43	35%	5 mo	8.3 mo

Note. RR = response rate; TTP = time to progression; MS = median survival; Cet = cetuximab; Pac = paclitaxel; Carb = carboplatin; AUC = area under the concentration-time curve; NPC = nasopharyngeal carcinoma; NA = not available; Ifos = ifosfamide; NSCLC = non-small cell lung cancer; Bev = bevacizumab; Gem = gemcitabine; Cis = cisplatin; Pem = pemetrexed; Dex = dexamethasone; Doc = docetaxel; Vin = vinorelbine; Oxali = oxaliplatin.

Acknowledgments

We would like to acknowledge Dr. Aurelio Matamoros for his assistance in radiographic imaging, Dr. Robert A. Wolff for sharing his patient experience, and Jonathan Phillips for editing.

DISCLOSURE

The authors have no conflicts of interest to disclose.

REFERENCES

- Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B. III, Thomas, C. R.,...Willett, C. (2008). Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. *Journal of the American Medical Association*, 299(16), 1914–1921. <http://dx.doi.org/10.1001/jama.299.16.1914>
- Ajani, J. A., Wang, X., Izzo, J. G., Crane, C. H., Eng, C., Skibber, J. M.,...Rashid, A. (2010). Molecular biomarkers correlate with disease-free survival in patients with anal carcinoma treated with chemoradiation. *Digestive Diseases and Sciences*, 55, 1098–1105. <http://dx.doi.org/10.1007/s10620-009-0812-6>
- Alcindor, T. (2008). Activity of paclitaxel in metastatic squamous anal carcinoma. *International Journal of Colorectal Disease*, 23(7), 717. <http://dx.doi.org/10.1007/s00384-008-0467-3>
- Alvarez, G., Perry, A., Tan, B. R., & Wang, H. L. (2006). Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. *Modern Pathology*, 19, 942–949. <http://dx.doi.org/10.1038/modpathol.3800608>
- Bilimoria, K. Y., Bentrem, D. J., Rock, C. E., Stewart, A. K., Ko, C. Y., & Halverson, A. (2009). Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: Analysis of patients from the National Cancer Data Base. *Diseases of the Colon & Rectum*, 52, 624–631. <http://dx.doi.org/10.1007/DCR.0b013e31819eb7f0>
- Couteau, C., Chouaki, N., Leyvraz, S., Oulid-Aissa, D., Lebecq, A., Domenge, C.,...Armand, J.-P. (1999). A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. *British Journal of Cancer*, 81(3), 457–462. <http://dx.doi.org/10.1038/sj.bjc.6690715>
- Deniaud-Alexandre, E., Touboul, E., Tired, E., Sezeur, A., Houry, S., Gallot, D.,...Schlienger, M. (2003). Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. *International Journal of Radiation Oncology Biology Physics*, 56, 1259–1273. [http://dx.doi.org/10.1016/S0360-3016\(03\)00417-6](http://dx.doi.org/10.1016/S0360-3016(03)00417-6)
- Eng, C., & Pathak, P. (2008). Treatment options in metastatic squamous cell carcinoma of the anal canal. *Current Treatment Options in Oncology*, 9, 400–407. <http://dx.doi.org/10.1007/s11864-009-0103-7>
- Evans, T. R. J., Mansi, J. L., & Glees, J. P. (1993). Response of metastatic anal carcinoma to single agent carboplatin. *Clinical Oncology*, 5(1), 57–58. [http://dx.doi.org/10.1016/S0936-6555\(05\)80699-5](http://dx.doi.org/10.1016/S0936-6555(05)80699-5)
- Faivre, C., Rougier, P., Ducreux, M., Mitry, E., Lusinchi, A., Lasser, P.,...Eschwege, F. (1999). 5-fluorouracil and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer [in French]. *Bulletin du Cancer*, 86(10), 861–865.
- Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E.,...Belani, C. P. (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. *Journal of Clinical Oncology*, 21(16), 3016–3024 [E-pub ahead of print]. <http://dx.doi.org/10.1200/JCO.2003.12.046>
- Fountzilas, G., Skarlos, D., Athanassiades, A., Kalogera-Fountzila, A., Samantas, E., Bacoyiannis, C.,...Daniilidis, N. (1997). Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. *Annals of Oncology*, 8(5), 451–455. <http://dx.doi.org/10.1023/A:1008279503428>
- Graf, R., Wust, P., Hildebrandt, B., Gögl, H., Ullrich, R., Herrmann, R.,...Felix, R. (2003). Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. *Oncology (Basel)*, 65, 14–22. <http://dx.doi.org/10.1159/000071200>
- Gridelli, C., Gallo, C., Shepherd, F. A., Illiano, A., Piantedosi, F., Robbiati, S. F.,...Perrone, F. (2003). Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. *Journal of Clinical Oncology*, 21(16), 3025–3034 [E-pub ahead of print]. <http://dx.doi.org/10.1200/JCO.2003.06.099>
- Hainsworth, J. D., Burris, H. A. III, Meluch, A. A., Baker, M. N., Morrissey, L. H., & Greco, A. (2001). Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: Results of a phase II trial. *Cancer*, 92(3), 642–649. [http://dx.doi.org/10.1002/1097-0142\(20010801\)92:3<642::AID-CNCR1365>3.0.CO;2-Z](http://dx.doi.org/10.1002/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z)
- Herbst, R. S., O'Neill, V. J., Fehrenbacher, L., Belani, C., Bonomi, P., Hart, L.,...Sandler, A. (2007). Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. *Journal of Clinical Oncology*, 25(30), 4743–4750 [E-pub ahead of print]. <http://dx.doi.org/10.1200/JCO.2007.12.3026>
- Horner, M. J., Ries, L. A. G., Krapcho, M., Neyman, N., Aminou, R., Howlader, N.,...Edwards, B. K. (2009). SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute. Retrieved from http://seer.cancer.gov/csr/1975_2006/
- James, R., Wan, S., Glynne-Jones, R., Sebag-Montefiore, D., Kadalayil, L., Northover, J.,...Ledermann, J. (2009). A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [Abstract LBA4009]. *Journal of Clinical Oncology*, 18s(suppl).
- Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008). Cancer Statistics, 2008. *CA: A Cancer Journal for Clinicians*, 58, 71–96. <http://dx.doi.org/10.3322/CA.2007.0010>
- Kelly, K., Crowley, J., Bunn, P. A. Jr, Persant, C. A., Grevstad, P. K., Moynour, C. M.,...Gandara, D. R. (2001). Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. *Journal of Clinical Oncology*,

- 19(13), 3210–3218.
- Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C.,...Woytowitz, D. (2010). Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. *Journal of Clinical Oncology*, 28, 911–917 [E-pub ahead of print]. <http://dx.doi.org/10.1200/JCO.2009.21.9618>
- Monnerat, C., Le Chevalier, T., Kelly, K., Obasaju, C. K., Brahmer, J., Novello, S.,...Ettinger, D. S. (2004). Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. *Clinical Cancer Research*, 10(16), 5439–5446. <http://dx.doi.org/10.1158/1078-0432.CCR-04-0218>
- Phan, L. K., & Hoff, P. M. (2007). Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: Report of a case. *Diseases of the Colon & Rectum*, 50(3), 395–398. <http://dx.doi.org/10.1007/s10350-006-0786-9>
- Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R.,...Gatzemeier, U. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. *Lancet*, 373, 1525–1531. [http://dx.doi.org/10.1016/S0140-6736\(09\)60569-9](http://dx.doi.org/10.1016/S0140-6736(09)60569-9)
- Reck, M., von Pawel, J., Zatloukal, P., et al. (2010). Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). *Annals of Oncology*, 21(9), 1804–1809 [E-pub ahead of print]. <http://dx.doi.org/10.1093/annonc/mdq020>
- Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B. C.,...Reck, M. (2008). Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. *Annals of Oncology*, 19, 362–369 [E-pub ahead of print]. <http://dx.doi.org/10.1093/annonc/mdm474>
- Ryan, D., & Willet, C. (2001). Anal cancer. In G. Steele Jr, T. Phillips, & B. Chabner (Eds.), *Cancer of the lower gastrointestinal tract. Atlas of clinical oncology*. American Cancer Society (pp. 196–213). Hamilton-London: B.C. Decker.
- Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A.,...Johnson, D. H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *New England Journal of Medicine*, 355(24), 2542–2550. <http://dx.doi.org/10.1056/NEJMoa061884>
- Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U.,...Einhorn, L. H. (2000). Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. *Journal of Clinical Oncology*, 18(1), 122–130.
- Schornagel, J. H., Verweij, J., de Mulder, P. H. M., Cognetti, F., Vermorken, J. B., Cappelaere, P.,...Lefebvre, J. L. (1995). Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. *Journal of Clinical Oncology*, 13(7), 1649–1655.
- Shin, D. M., Glisson, B. S., Khuri, F. R., Lippman, S. M., Ginsberg, L., Diaz, E. Jr.,...Hong, W. K. (2002). Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. *Cancer*, 95(2), 322–330. <http://dx.doi.org/10.1002/cncr.10661>
- Van Damme, N., Van Roy, N., Speleman, F., Bols, A., Van Dorpe, J., Pauwels, P., & Peeters, M. (2008). EGFR and K-RAS gene status evaluation in anal canal squamous cell carcinoma [Abstract 15569]. *Journal of Clinical Oncology*, 26(May 20 suppl).
- Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., ...Hitt, R. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. *New England Journal of Medicine*, 359, 1116–1127.
- Zatloukal, P., Petruželka, L., Zemanová, M., Kolek, V., Skříčková, J., Pešek, M.,...Kůta, M. (2003). Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer: A phase III randomized trial. *Lung Cancer*, 41(3), 321–331. [http://dx.doi.org/10.1016/S0169-5002\(03\)00233-2](http://dx.doi.org/10.1016/S0169-5002(03)00233-2)
- Zinner, R. G., Novello, S., Peng, G., Herbst, R., Obasaju, C., & Scagliotti, G. (2010). Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. *Clinical Lung Cancer*, 11(2), 126–131. <http://dx.doi.org/10.3816/CLC.2010.n.017>